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Key messages
What is already known about this subject?
 ► in the pre-bDMarD  (biological disease-modifying 
antirheumatic drug) era, employment of patients 
with ankylosing spondylitis (aS) was reduced com-
pared with the general population.
 ► Personal attitudes or beliefs, such as passive coping 
or helplessness among patients with aS, have been 
associated with adverse work outcome.
What does this study add?
 ► this study demonstrates that employment of pa-
tients with  aS in the netherlands in the bDMarD 
era remains reduced compared with the general 
population.
 ► Mastery, an indicator of control over stressors of life, 
is associated with being employed in patients but 
not in controls.
How might this impact on clinical practice?
 ► also in the 21st century, employment in patients with 
aS deserves attention, and programmes aimed at 
work participation might need to focus on self-man-
agement skills.
AbstrAct
Objectives to update the knowledge on employment and 
the role of mastery, a personal factor reflecting the level 
of control over life and disease, among Dutch patients 
with ankylosing spondylitis (aS) compared to general 
population subjects.
Methods Data of persons ≤65 years participating in 
a Dutch cross-sectional multicentre study on social 
participation in aS were used. Being employed was the 
main outcome. Standardised employment ratios (Sers) 
were calculated using indirect standardisation after 
adjusting for age, gender and education and repeated 
after stratification by symptom duration tertiles. Modified 
Poisson regressions were performed to understand 
the role of mastery (Pearlin’s scale) independent of 
sociodemographic and health-related factors.
Results 214 patients and 470 controls (127 (59.3%) 
and 323 (68.7%) males; mean age 48.3 (SD 10.4) 
and 39.3 (SD 12.7) years, respectively) completed an 
online questionnaire. Ser (95%ci) in patients was 0.83 
(0.69–0.98); 0.84 (0.67–1.04) in males; 0.83 (0.59–1.07) 
in females. adjusted absolute employment of patients 
compared to controls was 69% versus 84%; 73% 
versus 86% for males; 62% versus 78% for females. in 
multivariable analyses stratified for patients and controls, 
mastery was associated with being employed in patients, 
but only in those with low education. in controls, not 
mastery but higher education was associated with being 
employed.
Conclusion Our study reveals that patients suffering 
from aS compared to population controls are less likely 
to be employed. Mastery is an important personal factor 
associated with employment in patients but not in controls. 
interventions aimed at improving employment of patients 
with aS should likely account for mastery.
InTROduCTIOn
For patients with ankylosing spondylitis (AS), 
employment ranks among the three most 
important social roles.1 Preceding studies 
showed that patients with AS encounter 
difficulties to remain employed.2 When 
compared with population controls, a Dutch 
study from 2001 revealed that age-adjusted 
and gender-adjusted employment in patients 
with established AS was 11% lower.3 More-
over, a decrease in employment was already 
seen early in the disease.4 In the same period, 
other European studies confirmed reduced 
employment of patients compared with the 
general population.5, 6 Since then, efforts 
have been made to improve timely diagnosis 
and treatment of AS. Importantly, biolog-
ical disease-modifying antirheumatic drugs 
(bDMARDs) have been introduced, which 
had overall beneficial effect on presenteeism 
and sick leave in patients with higher disease 
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activity.7 Given this progress, it would be expected that 
employment rates in AS are improving and possibly 
even become similar to those of the general population. 
This would be especially expected in patients with short 
symptom duration, as the effects of improvement in 
care over the last decade would be expected to be most 
pronounced in this subgroup.
Participation in labour force of patients with a chronic 
disease is a complex outcome, and several theoret-
ical frameworks are available to help understand the 
complex interplay between biomedical and different 
personal and environmental factors.8, 9 Disease-related 
determinants, such as disease activity and physical func-
tion, can only partially explain the impact of AS on 
work. 10 Past studies provided empirical evidence that 
lack of control, reflected by passive coping, self-efficacy 
or helplessness were strongly associated with adverse 
work outcome, independent of disease-specific impair-
ments.4, 11, 12 However, it remains unclear whether the 
effect of personal attitudes or beliefs has a generic (ubiq-
uitous) effect on work participation or plays a different 
role in patients compared with general population 
subjects. Such information would be relevant to empha-
sise the role of self-management specifically in persons 
with a chronic disease and would support reinforcing the 
role of self-efficacy in patient education programmes for 
employed patients with AS for whom continuation in the 
workforce is an important goal.13
In the current study, the first objective was to update 
the current knowledge on employment of patients with 
AS in comparison to the general population in the Neth-
erlands, also in relation to symptom duration. The second 
objective was to understand whether mastery, reflecting 
level of control over life and disease, would have a similar 
association with employment in patients as in controls.
MeTHOds
study population
Data from the Social Participation in AS Study (SPASS), a 
multicentre cross-sectional survey-based study including 
patients with AS in the Netherlands, were used for this 
analysis.1 Patients were recruited from six hospitals 
during a 6-month period in 2011. Patients were eligible if 
at least 18 years of age and if the treating rheumatologist 
confirmed fulfilment of the modified New York criteria 
for AS.14 Exclusion criteria were insufficient ability to 
read/understand the Dutch language, no access to a 
computer with online connection and severe immediate 
life-threatening comorbidities according to the treating 
physician. A control population was recruited in parallel 
by Ipsos, an ISO-certified independent company special-
ised in population surveys for global market, policy and 
research purposes. Population controls were sampled to 
yield an age and gender distribution as expected from 
previously published observational studies in AS (mean 
age 42 years, male to female ratio 3:1).15 The study was 
approved by the ethical committee of the Maastricht 
University Medical Center and all participants provided 
informed consent.
Assessments
All participants completed a similar online survey, with 
questions on sociodemographics including income 
(four categories), education (primary school, lower 
(professional) education, secondary (vocational) educa-
tion, higher education/university) and a question on 
employment (currently employed, yes/no). Lifestyle 
was assessed using questions on smoking and drinking 
behaviour. Generic health status was assessed using the 
Short Form-36 (SF-36), providing a Physical Component 
Summary (SF-36PCS) and Mental Component Summary 
(SF-36MCS).16 Disease-related questions included ques-
tions on symptom duration (defined as time in years 
since symptom onset) and medication use. Disease 
activity and functioning were measured among patients 
using the Bath AS Disease Activity Index (BASDAI) 
and Bath AS Functional Activity Index (BASFI), respec-
tively.17, 18 Presence, treatment and functional impact of 
comorbidities and extra-articular manifestations (psori-
asis, uveitis and inflammatory bowel disease (IBD)), were 
assessed using the Self-Administered Comorbidity Ques-
tionnaire (SCQ).19 Mastery, the extent to which one feels 
their life chances as being under their personal control, 
was assessed using the 7-item Pearlin’s mastery scale.20 
This instrument measures the extent to which individ-
uals perceive themselves in control of forces that signif-
icantly impact their lives. Each item can be scored on a 
1 to 4 scale (1: strongly disagree; 2: disagree; 3: agree; 4: 
strongly agree) resulting in a score range of 7 (worst) to 
28 (best). The individual items of Pearlin’s mastery scale 
are presented in online supplementary file 1.
statistical analysis
Being employed (yes/no) was the main outcome for 
the current analyses, which is why the study sample was 
restricted to those aged≤65 years (the legal age of retire-
ment in the Netherlands in 2011). Differences in demo-
graphic and health characteristics between patients and 
population controls were explored with independent 
t-test, Mann Whitney test or χ² test, depending on level of 
measurement and distribution. If appropriate (expected 
count<5), Fisher’s exact test was preferred over χ² test.
standardised employment ratios
The impact of AS on work participation when compared 
with population controls was assessed for the total group 
and subsequently for three strata of symptom duration 
(tertiles: 0–14, 15–27 and 28–50 years), by computing 
standardised employment ratios (SERs) with 95% CI 
using indirect standardisation methods. Standardisation 
accounted for gender, age (categorised:<35, 35–<50 and 
50–65 years of age) and education (university/college 
level versus no/lower/secondary education). The SER 
can be interpreted as the relative chance of patients 
with AS having a paid job compared with the control 
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group (set as reference, value=1.00). To investigate the 
effect of disease activity on employment, SERs were also 
presented for patients with a BASDAI≥4 and patients 
with a BASDAI<4 separately. Using the SER, the adjusted 
absolute employment rate for patients was computed by 
multiplying the SER for patients by the absolute employ-
ment rate of controls.
differential effect of contributory factors in patients and 
controls
To assess the differential impact of mastery on employ-
ment in patients or controls, a regression model was 
developed with employment (yes/no) as dependent vari-
able. As incidence rate ratios (IRRs, generated by modi-
fied Poisson regression) more accurately reflect risks than 
ORs (generated by logistic regression) when the preva-
lence of the outcome is >10%, modified Poisson regres-
sion was preferred over logistic regression.21 Exploratory 
analysis revealed that patients on TNFi were in a worse 
health state compared with patients not on TNFi. Likely, 
these patients had even worse disease at the start of TNFi, 
and the role of TNFI at the individual level cannot further 
be explored as this covariate is subject to confounding by 
indication. Consequently, TNFi use was not included in 
the multivariable models to prevent biased results. Also, 
as the aim of this analysis was to compare the differential 
effect of factors in patients and controls, generic varia-
bles (such as SF-36PCS) were preferred over disease-spe-
cific factors (such as BASDAI). Variables of interest were 
thus education (dichotomised, higher education/univer-
sity versus other), smoking, alcohol use, body mass index, 
comorbidity, health status (SF36-PCS, SF36-MCS) and 
mastery. These were first explored in univariable analysis, 
correcting for gender and age. Next, a basic multivariable 
model was computed in the total sample including age, 
gender and group-membership (patient versus control). 
Subsequently, demographic variables and health varia-
bles (SF-36PCS, comorbidity) that were associated with 
being employed in univariable analyses (p<0.20) were 
added using a manual forward method, after ruling out 
collinearity between variables. Variables were retained if 
significantly associated with the outcome (p<0.05) and/
or a confounder (changed the IRR of included varia-
bles>10%). As a final step, mastery was added.
Interactions between group-membership and all vari-
ables in the model were tested, and p<0.10 was consid-
ered sufficient reason to explore stratified analyses. As 
significant interactions were found between group-mem-
bership and mastery (p=0.02) as well as SF-36PCS 
(p=0.08), further analyses were carried out in patients 
and controls separately. As an additional interaction was 
observed between education and mastery in the patient 
group (p=0.08), the final analyses were carried out in 
three separate subsamples: controls, patients with lower 
education and patients with higher education. All statis-
tical analyses were performed with SPSS V.23.0 (IBM, 
Armonk, New York, USA) and Stata Release 14 (Stata, 
College Station, Texas, USA).
ResulTs
Comparison of patients with As versus controls
In total, 214 subjects diagnosed with AS and 470 controls 
of 65 years or younger participated. Against expectations, 
patients were significantly older than controls (48.3 vs 
39.3 years, p<0.01) and less frequently male (59.3% vs 
68.7%, p=0.02). Patients more frequently had low income 
and low education. Further, comorbidity score was higher 
and SF-36PCS and mastery were worse in patients with AS 
compared with population controls (table 1).
standardised employment ratios
The SER (95% CI) in patients with AS, having controls 
as reference (value 1.00), was 0.83 (0.69 to 0.98) overall; 
0.84 (0.67 to 1.04) for males and 0.80 (0.59 to 1.07) 
for females (figure 1A). The adjusted absolute employ-
ment rates for patients and controls were 69% vs 84% 
in the total population; 73% vs 86% for males and 62% 
vs 78% for females. Although not statistically signif-
icant, SERs in males were lowest in the tertile of those 
with longest symptom duration. This was not observed 
in females. Along the same line, SERs were slightly (but 
not significantly) lower in females than in males, except 
for the subgroup with a symptom duration of 15–27 
years (figure 1A). It should be noted that also absolute 
(adjusted) employment was somewhat lower in females 
compared with males (figure 1B). The SER in patients 
with a BASDAI≥4 was significantly lower compared with 
controls. In contrast, in patients with a BASDAI<4, the 
SER was almost similar to controls (figure 2).
differential effect of mastery in patients and controls
The results of univariable analyses are shown in table 2. 
Multivariable stratified analyses by group-membership 
and further by education in patients are presented in 
table 3. Among controls, better SF-36 PCS and higher 
educational attainment were associated with increased 
employment rates (IRR=1.01, 95% CI 1.00 to 1.02 for 
SF-36PCS; IRR=1.09, 95% CI 1.01 to 1.18 for higher 
education). No association between mastery and employ-
ment was observed in controls. However, in patients 
with AS with lower education a significant association 
was seen between mastery and employment (IRR=1.04, 
95% CI 1.01 to 1.08), while this was not observed in those 
with higher education (mastery forced into multivariable 
model: IRR=1.01, 95% CI 0.98 to 1.04). In addition to 
education, higher age was associated with a decreased 
employment, while better SF-36PCS with an increased 
chance of being employed (table 3).
To confirm the role of mastery in patients with a low 
level of education, a scenario analysis was carried out for 
which BASDAI or BASFI (separate models due to collin-
earity between these variables) was used in the models 
instead of SF-36PCS. This analysis led to similar results 
(table 4). Of note, mastery was not significant nor a 
confounder in patients with a high level of education, 
and if forced into the models, its effect size was small to 
none (data not shown).
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Table 1  Characteristics of the patients with AS and population controls aged≤65 years
Variable
AS
(n=214)
Controls
(n=470) P values*
Age, years 48.3 (10.4) 39.3 (12.7) <0.01
Male, n (%) 127 (59.3) 323 (68.7) 0.02
Education, n (%) <0.01†
  Primary school 2 (0.9) 0 (0.0)
  Lower (professional) education 36 (16.8) 30 (6.4)
  Secondary education 107 (50.0) 207 (44.0)
  Higher education/university 69 (32.2) 233 (49.6)
Current smoker, n (%) 43 (20.1) 90 (19.2) 0.78
Alcohol use (yes), n (%) 168 (78.5) 389 (82.8) 0.18
BMI, kg/m2 26.3 (4.4) 25.3 (4.3) <0.01
Currently employed, n (%) 139 (65.0) 393 (83.6) <0.01
Work disability, n (%) 58 (27.1) 17 (3.6) <0.01
Annual income, n (%) <0.01
  ≤€20 000 64 (29.9) 44 (11.3)
  >€20 000 and ≤€40 000 65 (30.4) 113 (29.0)
  >€40 000 and ≤€60 000 39 (18.2) 123 (31.5)
  >€60 000 46 (21.5) 110 (28.2)
Symptom duration, years 21.4 (11.2) n/a n/a
Time since diagnosis, years 15.5 (10.7) n/a n/a
Current medication use, n (%) n/a
  NSAID 117 (54.7) n/a
  Anti-TNF 119 (55.6) n/a
SCQ (0-39)‡ 2.7 (4.1) 1.0 (1.7) <0.01
History of psoriasis, n (%) 18 (8.4) n/a n/a
History of uveitis, n (%) 38 (17.8) n/a n/a
History of IBD, n (%) 31 (14.5) n/a n/a
BASDAI 4.3 (2.2) n/a n/a
BASFI 4.1 (2.5) n/a n/a
SF-36PCS (0–100) 39.5 (10.6) 53.9 (8.4) <0.01
SF-36MCS (0–100) 49.2 (12.8) 49.4 (11.7) 0.32
Mastery (7–28) 20.8 (4.0) 22.4 (3.9) <0.01
Values expressed as mean (SD) unless otherwise stated.
*Two-tailed patients versus controls. Continuous data: independent t-tests for normally distributed variables and Mann-Whitney tests for 
non-normally distributed variables. Categorical data: χ² tests and Fisher’s exact tests (latter for small samples, expected count<5).
†Result of χ² test, 4×2 table. Posthoc test for difference in level of education (high vs other) between groups was significant (p<0.001).
‡Modified SCQ, excluding questions on back pain, chronic rheumatic disease and osteoarthritis.
AS, ankylosing spondylitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional 
Index; BMI, body mass index; IBD, inflammatory bowel disease; n/a, not applicable; NSAID, non-steroidal anti-inflammatory drug; SCQ, Self-
Administered Comorbidity Questionnaire; SF-36PCS, Short Form (36) Physical Component Summary; SF-36MCS, Short Form (36) Mental 
Component Summary; TNF, tumour necrosis factor.
dIsCussIOn
Employment among patients with AS in the Nether-
lands was 14.4% lower than in a general population 
sample after adjustment for age, gender and education. 
Although this adverse effect on employment was also 
observed in patients with AS with shorter symptom dura-
tion, the impact seemed stronger in those with longest 
symptom duration. Mastery, a personal factor assessing 
level of control over life and disease, was associated with 
employment in patients with AS who had a lower educa-
tional level, but not in controls.
Considering the innovations in diagnosis and biomed-
ical management of patients with AS over the last two 
decades, one would expect the difference in employment 
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Figure 1  Employment of patients with AS compared with controls. SERs with 95% CIs of patients with AS with controls 
set as reference (dotted line, 1A) and adjusted absolute employment rates for patients with AS and controls (1B), stratified by 
symptom duration and gender. Calculation of adjusted absolute employment=SERAS × employment rate of controls. Due to 
missing data, 203 (of 214) patients were included in this analysis.  *P<0.05 compared to controls. AS, ankylosing spondylitis; 
SERs, standardised employment ratios.
between patients and general population to have become 
smaller. Instead, almost 15 years after a comparable 
study among Dutch AS patients (data from 1997) which 
reported a reduction in employment of 11%, our find-
ings were of similar magnitude.3 It should be empha-
sised that overall employment in the general population 
increased substantially over this 15-year period. While 
employment rate for the general population in the 
previous study was 66% (54% in AS, adjusted), this was 
84% in the current study (69% in AS, adjusted). Likely 
the concurrent increase in employment in the general 
population, but also the higher work load in times of 
economic austerity that likely affects patients more 
severely, attenuates the expected improvement on work 
participation of patients when compared with controls. 
A recent study from Germany investigating employment 
(among other outcomes) in a mixed prevalence and inci-
dence cohort of patients with AS in the period 2000–2012 
revealed overall employment ratios comparable to our 
results.22 Somewhat contrary to our study, they found 
that the overall difference in employment rates between 
patients with AS and general population was decreasing, 
and even non-existent in the younger subgroups. When 
stratifying our sample for symptom duration, employ-
ment rates were even decreased in those with less than 15 
years’ symptom duration. This suggests that employment 
remains challenging despite improved medical treat-
ment. Notwithstanding, the decrease in employment 
was somewhat stronger in those with a longer symptom 
duration. This may reflect that patients diagnosed in 
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Figure 2  Employment of patients with AS compared 
with controls, by BASDAI. SERs with 95% CIs of patients 
with AS with controls set as reference (dotted line), stratified 
by symptom duration and BASDAI. Due to missing data, 
203 (of 214) patients were included in this analysis. 
*P<0.05 compared to controls. AS, ankylosing spondylitis; 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; 
SERs, standardised employment ratios. 
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the last 15 years have benefitted from the availability of 
biologicals.
Although previous studies in AS pointed towards a 
greater reduction in work participation among men 
than women, the current study suggests no gender differ-
ence.3, 6 The non-significant higher employment ratio 
of 1.08 in women with a symptom duration between 16 
and 30 years was unexpected. Of note, the sample size 
of this subgroup was small (n=25 patients, of which 8 
were with higher education), as reflected by the large CI 
surrounding the IRR and chance likely played a role.
An adverse impact of comorbidities on employment 
in spondyloarthritis has recently been described in a 
cross-sectional international study.23 In the current 
study, comorbidities were associated with employment 
in univariable analysis in both controls and patients with 
AS, but such association was not confirmed in multivari-
able analysis in either of the populations. Possible expla-
nations for this discrepancy could be the differences in 
study populations and instruments used to assess comor-
bidity. Also, the influence of comorbidities on outcome 
might not be similar across countries.24
The current analyses confirm the role of personal 
contextual factors in relation to employment among 
patients with AS. Specifically, lower mastery was associ-
ated with not being employed. Importantly, mastery was 
only relevant in patients with lower education, another 
personal contextual factor. Apparently, in lower educated 
persons, low mastery is a barrier to overcome challenges 
to remain active in the labour force. To the best of our 
knowledge, this is the first study to reveal that mastery is 
not a ‘generic’ determinant of work outcome, as clearly 
mastery played no role in employment outcome among 
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controls. It seems that persons with a chronic disease are 
more vulnerable to the effect of lower mastery.
In addition to the role of context, physical health 
(SF-36 PCS) remains suboptimal in patients compared 
with controls and contributes importantly to the lower 
employment. Although biologicals were widespread 
available in 2011, active disease was present in a signifi-
cant number of patients in SPASS (BASDAI≥4 in 57.5% 
of patients). Within the limits of interpretability in a 
cross-sectional study, subgroup analysis of the data also 
suggested employment in patients is particularly reduced 
in those with BASDAI≥4. Currently, the treat-to-target 
principle is being investigated in axial spondyloarthritis 
(axSpA). It is important that studies on treat-to-target in 
axSpA also consider work participation as an outcome. 
If treat-to-target (ie, to low disease activity) for axSpA 
turns out to be effective, the difference in employment 
between patients with AS and the general population 
should become smaller.
Strengths of our study were inclusion of a general 
population sample, participation of centres with 
different settings (academic and private hospitals) and 
from various geographical regions and availability of all 
predictors in patients as well as controls. Nevertheless, 
there are some limitations. First, it should be emphasised 
that the current observations apply only to patients under 
care of a rheumatologist. Further, matching of patients 
to control subjects was less successful than intended, but 
extensive adjustment was performed in all analyses. Also, 
given our retrospective approach, reverse causality (loss 
of employment or unable to become employed having 
negative influence on mastery) cannot be excluded. 
Comparison with the 1997 Dutch data, while insightful, 
should be done with some caution as data collection was 
not similar (for 1997 aggregated data from the Central 
Bureau of Statistics was used for standardization, while 
for the current study direct sampling allowed to collect 
more patient level characteristics).[3] Next, as cultural, 
societal and legal provisions are likely to influence 
employment status in both patients and the general popu-
lation, generalisability of our results to other countries 
is limited. Finally, although we had information on use 
of TNFi medication (55% users in AS group), the effect 
of TNFi medication on employment could not be inves-
tigated, due to confounding by indication. It should be 
noted that data on the health state and disease activity of 
these patients before TNFi initiation were not available. 
Consequently, no conclusions regarding the benefits of 
TNFi use regarding employment can be drawn. Note that 
this limitation does not impact our primary analysis of 
employment rates in patients versus controls.
In summary, our findings showed that despite the wide-
spread availability of bDMARDs, employment of Dutch 
patients with AS was decreased when compared with 
general population controls. Not only biomedical but also 
contextual factors explain employment. Higher mastery 
was associated with better employment in patients only, 
especially those with lower educational level. Programmes 
aimed at work participation in AS might need to focus on 
self-management skills to be effective. Further research 
is necessary to develop interventions and confirm their 
effectiveness.
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